These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 4148443

  • 1. Letter: Effects of antiparkinsonian drugs on neuroleptic-induced extrapyramidal signs in monkeys.
    Shintomi K, Yamamura M.
    J Pharm Pharmacol; 1973 Aug; 25(8):666-7. PubMed ID: 4148443
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Drug levels and antiparkinsonian drugs in neuroleptic-treated schizophrenic patients.
    Hitri A, Craft RB, Sethi R, Sinha D.
    Clin Neuropharmacol; 1987 Jun; 10(3):261-71. PubMed ID: 2900683
    [Abstract] [Full Text] [Related]

  • 4. A quantitative study of neuroleptic-induced extrapyramidal symptoms and their response to dexetimide, a potent and long-acting antiparkinsonian agent.
    Dom R, Van Lommel R, Baro F.
    Acta Psychiatr Scand; 1971 Jun; 47(4):399-410. PubMed ID: 4947805
    [No Abstract] [Full Text] [Related]

  • 5. Antiparkinson drugs in paranoid schizophrenia.
    Cavenar JO, Braasch ER, Sullivan JL.
    N C Med J; 1979 May; 40(5):287-8. PubMed ID: 35758
    [No Abstract] [Full Text] [Related]

  • 6. A comparison of the inhibitory effects of certain antiparkinsonian agents on dopamine accumulation into the rat striatum.
    Nose T, Segawa T.
    Jpn J Pharmacol; 1974 Apr; 24(2):299-305. PubMed ID: 4152745
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Letter: Abrupt withdrawal of antiparkinsonian drugs in chronic schizophrenic patients.
    McLelland HA, Blessed G, Bhate S.
    Br J Psychiatry; 1974 Nov; 125():514-5. PubMed ID: 4461148
    [No Abstract] [Full Text] [Related]

  • 9. Trihexyphenidyl interactions with the dopamine D1-selective receptor agonist SKF-82958 and the D2-selective receptor agonist N-0923 in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced hemiparkinsonian monkeys.
    Domino EF, Ni L.
    J Pharmacol Exp Ther; 1998 Jan; 284(1):307-11. PubMed ID: 9435192
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Drug-induced extrapyramidal disorders.
    Chase TN.
    Res Publ Assoc Res Nerv Ment Dis; 1972 Jan; 50():448-71. PubMed ID: 4341954
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Prophylactic antiparkinson drug use: I. Initial prophylaxis and prevention of extrapyramidal side effects.
    Lavin MR, Rifkin A.
    J Clin Pharmacol; 1991 Aug; 31(8):763-8. PubMed ID: 1679062
    [Abstract] [Full Text] [Related]

  • 15. Amantadine in drug-induced extrapyramidal signs: a comparative study.
    Ananth J, Sangani H, Noonan JP.
    Int J Clin Pharmacol Biopharm; 1975 Jun; 11(4):323-6. PubMed ID: 239908
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.